SCHEDULE: BlackRock Reports Stake in Maxcyte

BlackRock Inc. has disclosed a beneficial ownership of 1.3% in Maxcyte, Inc. as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Maxcyte, Inc. common stock.
• The filing, dated June 30, 2026, shows BlackRock beneficially owns 1,402,591 shares.
• This represents 1.3% of the total outstanding common shares of Maxcyte, Inc.
• BlackRock has sole voting power and sole dispositive power over these shares.
• The filing clarifies that this ownership is held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral score as the filing is a routine disclosure of institutional ownership and does not provide operational or financial performance data for Maxcyte, Inc.

Positives

• BlackRock, a significant institutional investor, holds a stake in Maxcyte, Inc., which can be seen as a positive signal of confidence.
• The ownership is reported as being in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Risks

• The filing does not explicitly mention any risks associated with Maxcyte, Inc. itself, focusing solely on BlackRock's ownership status.

Future Outlook

The filing does not contain forward-looking statements or guidance from Maxcyte, Inc. It solely reports BlackRock's ownership stake.

Management Comments

• "BlackRock, Inc. ... does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries and affiliates, any and all documents..."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large asset managers like BlackRock are common and indicate significant institutional interest, but do not necessarily reflect a view on the company's operational performance or future prospects beyond a standard investment portfolio allocation.

Stakeholder Impact

• Shareholders: The filing indicates a significant institutional investor's presence, which can influence market perception and liquidity, but does not directly alter existing share ownership structures.

Key Dates

Keywords

Maxcyte, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Holding